Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Maizels, R.M. (2016)
Publisher: Elsevier
Journal: Clinical Microbiology and Infection
Languages: English
Types: Article
Subjects: Infectious Diseases, Microbiology (medical)

Classified by OpenAIRE into

mesheuropmc: parasitic diseases
The profile of global health today presents a striking reciprocal distribution between parasitic diseases in many of the world’s lower-income countries, and ever-increasing levels of inflammatory disorders such as allergy, autoimmunity and inflammatory bowel diseases in the more affluent societies. Attention is particularly focused on helminth worm parasites, which are associated with protection from allergy and inflammation in both epidemiological and laboratory settings. One mechanistic explanation of this is that helminths drive the regulatory arm of the immune system, abrogating the ability of the host to expel the parasites, while also dampening reactivity to many “bystander” specificities. Interest has therefore heightened into whether helminth parasites, or their products, hold therapeutic potential for immunological disorders of the developed world. In this narrative review, progress across a range of trials is discussed, together with prospects for isolating individual molecular mediators from helminths that may offer defined new therapies for inflammatory conditions.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] Maizels RM, Yazdanbakhsh M. T-cell regulation in helminth parasite infections: implications for inflammatory diseases. Chem Immunol Allergy 2008;94:112-23.
    • [2] Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43.
    • [3] Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002;51:3353-61.
    • [4] Economou M, Pappas G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 2008;14:709-20.
    • [5] Velasquez-Manoff M. An epidemic of absence: a new way of understanding allergies and autoimmune diseases. New York: Scribner; 2013.
    • [6] Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and 'westernlifestyle' inflammatory diseases. Immunity 2014;40:833-42.
    • [7] McKay DM. The therapeutic helminth? Trends Parasitol 2009;25: 109-14.
    • [8] McSorley HJ, Maizels RM. Helminth infections and host immune regulation. Clin Micro Rev 2012;25:585-608.
    • [9] Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. J Clin Invest 2008;118:1311 -21.
    • [10] King CH. It's time to dispel the myth of 'asymptomatic' schistosomiasis. PLoS Negl Trop Dis 2015;9:e0003504.
    • [11] Maizels RM, Yazdanbakhsh M. Regulation of the immune response by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 2003;3:733-43.
    • [12] Colley DG, Garcia AA, Lambertucci JR, Parra JC, Katz N, Rocha RS, et al. Immune responses during human schistosomiasis. XII. Differential responsiveness in patients with hepatosplenic disease. Am J Trop Med Hyg 1986;35:793-802.
    • [13] Sartono E, Kruize YCM, Kurniawan A, van der Meide PH, Partono F, Maizels RM, et al. Elevated cellular responses and interferon-γ release after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis. J Infect Dis 1995;171:1683-7.
    • [14] Mahanty S, Mollis SN, Ravichandran M, Abrams JS, Kumaraswami V, Jayaraman K, et al. High levels of spontaneous and parasite antigendriven interleukin-10 production are associated with antigen-specific hyporesponsiveness in human lymphatic filariasis. J Infect Dis 1996;173:769 -73.
    • [15] Babu S, Bhat SQ, Pavan Kumar N, Lipira AB, Kumar S, Karthik C, et al. Filarial lymphedema is characterized by antigen-specific Th1 and Th17 proinflammatory responses and a lack of regulatory T cells. PLoS Negl Trop Dis 2009;3:e420.
    • [16] Mbow M, Larkin BM, Meurs L, Wammes LJ, de Jong SE, Labuda LA, et al. T-helper 17 cells are associated with pathology in human schistosomiasis. J Infect Dis 2013;207:186-95.
    • [17] Platts-Mills TA, Woodfolk JA, Erwin EA, Aalberse R. Mechanisms of tolerance to inhalant allergens: the relevance of a modified Th2 response to allergens from domestic animals. Springer Semin Immunopathol 2004;25:271-9.
    • [18] Kurniawan A, Yazdanbakhsh M, van Ree R, Aalberse R, Selkirk ME, Partono F, et al. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J Immunol 1993;150:3941-50.
    • [19] Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998;160:3555 -61.
    • [20] Watanabe K, Mwinzi PN, Black CL, Muok EM, Karanja DM, Secor WE, et al. T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment. Am J Trop Med Hyg 2007;77:676-82.
    • [21] Wammes LJ, Hamid F, Wiria AE, Wibowo H, Sartono E, Maizels RM, et al. Regulatory T cells in human lymphatic filariasis: stronger functional activity in microfilaremics. PLoS Negl Trop Dis 2012;6:e1655.
    • [22] Metenou S, Nutman T. Regulatory T cell subsets in filarial infection and their function. Front Immunol 2013;4:305.
    • [23] Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-87.
    • [24] Maizels RM, Smith KA. Regulatory T cells in infection. Adv Immunol 2011;112:73-136.
    • [25] Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008;64: 187-99.
    • [26] Hussaarts L, van der Vlugt LE, Yazdanbakhsh M, Smits HH. Regulatory B-cell induction by helminths: implications for allergic disease. J Allergy Clin Immunol 2011;128:733-9.
    • [27] Labeaud AD, Malhotra I, King MJ, King CL, King CH. Do antenatal parasite infections devalue childhood vaccination? PLoS Negl Trop Dis 2009;3:e442.
    • [28] Johnston CJ, McSorley HJ, Anderton SM, Wigmore SJ, Maizels RM. Helminths and immunological tolerance. Transplantation 2014;97: 127-32.
    • [29] Salgame P, Yap GS, Gause WC. Effect of helminth-induced immunity on infections with microbial pathogens. Nat Immunol 2013;14: 1118-26.
    • [30] Wammes LJ, Hamid F, Wiria AE, de Gier B, Sartono E, Maizels RM, et al. Regulatory T cell in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum. Eur J Immunol 2010;40:437-42.
    • [31] Mishra PK, Palma M, Bleich D, Loke P, Gause WC. Systemic impact of intestinal helminth infections. Mucosal Immunol 2014;7:753-62.
    • [32] Greenwood BM. Autoimmune disease and parasitic infections in Nigerians. Lancet 1968;2:380-2.
    • [33] van den Biggelaar A, van Ree R, Roderigues LC, Lell B, Deelder AM, Kremsner PG, et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 2000;356:1723 -7.
    • [34] van den Biggelaar AH, Rodrigues LC, van Ree R, van der Zee JS, Hoeksma-Kruize YC, Souverijn JH, et al. Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis 2004;189:892-900.
    • [35] McKay DM. Not all parasites are protective. Parasite Immunol 2015;37:324-32.
    • [36] Araujo MI, Lopes AA, Medeiros M, Cruz AA, Sousa-Atta L, Solé D, et al. Inverse association between skin response to aeroallergen and Schistosoma mansoni infection. Int Arch Allergy Immunol 2000;123: 145-8.
    • [37] Cooper PJ, Chico ME, Rodrigues LC, Ordonez M, Strachan D, Griffin GE, et al. Reduced risk of atopy among school-age children infected with geohelminth parasites in a rural area of the tropics. J Allergy Clin Immunol 2003;111:995 -1000.
    • [38] Feary J, Britton J, Leonardi-Bee J. Atopy and current intestinal parasite infection: a systematic review and meta-analysis. Allergy 2011;66: 569-78.
    • [39] Cooper PJ, Barreto ML, Rodrigues LC. Human allergy and geohelminth infections: a review of the literature and a proposed conceptual model to guide the investigation of possible causal associations. Br Med Bull 2006;79 -80:203-18.
    • [40] Smits HH, Hammad H, van Nimwegen M, Soullie T, Willart MA, Lievers E, et al. Protective effect of Schistosoma mansoni infection on allergic asthma depends on intensity and chronicity of infection. J Allergy Clin Immunol 2007;120:932 -40.
    • [41] Flohr C, Tuyen LN, Quinnell RJ, Lewis S, Minh TT, Campbell J, et al. Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. Clin Exp Allergy 2010;40:131-42.
    • [42] Mutapi F, Imai N, Nausch N, Bourke CD, Rujeni N, Mitchell KM, et al. Schistosome infection intensity is inversely related to auto-reactive antibody levels. PLoS One 2011;6:e19149.
    • [43] Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007;61: 97-108.
    • [44] Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol 2011;233:6-11.
    • [45] Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U, McKerrow JH, et al. IL-22+ CD4+ T cells are associated with therapeutic Trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med 2010;2:60ra88.
    • [46] Weinstock JV, Elliott DE. Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol 2013;43:245-51.
    • [47] Fleming JO, Weinstock JV. Clinical trials of helminth therapy in autoimmune diseases: rationale and findings. Parasite Immunol 2015;37: 277-92.
    • [48] Summers RW, Elliott DE, Qadir K, Urban Jr JF, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 2003;98:2034 -41.
    • [49] Summers RW, Elliott DE, Urban Jr JF, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005;128:825 -32.
    • [50] Summers RW, Elliott DE, Urban Jr JF, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn's disease. Gut 2005;54:87-90.
    • [51] Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev 2014;1:CD009400.
    • [52] Bager P, Arnved J, Rønborg S, Wohlfahrt J, Poulsen LK, Westergaard T, et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010;125:123-30.
    • [53] Bourke CD, Mutapi F, Nausch N, Photiou DM, Poulsen LK, Kristensen B, et al. Trichuris suis ova therapy for allergic rhinitis does not affect allergen-specific cytokine responses despite a parasitespecific cytokine response. Clin Exp Allergy 2012;42:1582-95.
    • [54] Jouvin MH, Kinet JP. Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J Allergy Clin Immunol 2012;130:3-10.
    • [55] Benzel F, Erdur H, Kohler S, Frentsch M, Thiel A, Harms L, et al. Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients. J Helminthol 2012;86:339-47.
    • [56] Fleming J, Isaak A, Lee J, Luzzio C, Carrithers M, Cook TD, et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler 2011;17:743-54.
    • [57] Voldsgaard A, Bager P, Garde E, Akeson P, Leffers AM, Madsen CG, et al. Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Mult Scler 2015;21:1723-9.
    • [58] Fleming J, Hartman L, Maksimovic J, Nace S, Luzzio C, Koehn M, et al. Clinical trial of helminth-induced immunomodulatory therapy (HINT 2) in relapsing-remitting multiple sclerosis. Neurology 2014;82(Suppl P3):149.
    • [59] Feary J, Venn A, Brown A, Hooi D, Falcone FH, Mortimer K, et al. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clin Exp Allergy 2009;39:1060 -8.
    • [60] Feary JR, Venn AJ, Mortimer K, Brown AP, Hooi D, Falcone FH, et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy 2010;40:299-306.
    • [61] Croese J, O'Neil J, Masson J, Cooke S, Melrose W, Pritchard D, et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 2006;55:136-7.
    • [62] Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, et al. Effect of hookworm infection on wheat challenge in celiac disease-a randomised double-blinded placebo controlled trial. PLoS One 2011;6:e17366.
    • [63] Evans H, Mitre E. Worms as therapeutics for allergy: understanding why benefits in animal studies have not translated into clinical success. J Allergy Clin Immunol 2015;135:343 -53.
    • [64] Helmby H. Human helminth therapy to treat inflammatory disorders-where do we stand? BMC Immunol 2015;16:12.
    • [65] Leonardi I, Frey I, Rogler G. Helminth therapy for organic diseases? Transl Res 2015;166:586-601.
    • [66] Finlay CM, Walsh KP, Mills KH. Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases. Immunol Rev 2014;259:206-30.
    • [67] Johnston MJG, Macdonald JA, McKay DM. Parasitic helminths: a pharmacopeia of anti-inflammatory molecules. Parasitology 2009;136: 125-47.
    • [68] Heylen M, Ruyssers NE, Gielis EM, Vanhomwegen E, Pelckmans PA, Moreels TG, et al. Of worms, mice and man: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacol Ther 2014;143:153 -67.
    • [69] Harnett W, Harnett MM. Helminth-derived immunomodulators: can understanding the worm produce the pill? Nat Rev Immunol 2010;10: 278-84.
    • [70] McSorley HJ, Hewitson JP, Maizels RM. Immunomodulation by helminth parasites: defining mechanisms and mediators. Int J Parasitol 2013;43:301 -10.
    • [71] Shepherd C, Navarro S, Wangchuk P, Wilson D, Daly NL, Loukas A. Identifying the immunomodulatory components of helminths. Parasite Immunol 2015;37:293-303.
    • [72] Hewitson JP, Grainger JR, Maizels RM. Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol 2009;167:1-11.
    • [73] Schnoeller C, Rausch S, Pillai S, Avagyan A, Wittig BM, Loddenkemper C, et al. A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages. J Immunol 2008;180:4265-72.
    • [74] Harnett MM, Melendez AJ, Harnett W. The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease. Clin Exp Immunol 2010;159:256-67.
    • [75] Navarro S, Ferreira I, Loukas A. The hookworm pharmacopoeia for inflammatory diseases. Int J Parasitol 2013;43:225-31.
    • [76] McSorley HJ, Blair NF, Smith KA, McKenzie ANJ, Maizels RM. Blockade of IL-33 release and suppression of type 2 innate lymphoid cell responses by helminth secreted products in airway allergy. Mucosal Immunol 2014;7:1068-78.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
  • No similar publications.

Share - Bookmark

Funded by projects

  • WT | Helminths and the Immune Sys...

Cite this article